Piramal Pharma Ltd

NSE:PPLPHARMA (India)  
₹ 150.00 (+0.2%) May 28
1,355.46
P/B:
2.46
Market Cap:
₹ 198.06B ($ 2.38B)
Enterprise V:
₹ 238.73B ($ 2.87B)
Volume:
3.52M
Avg Vol (2M):
6.55M
Warning! GuruFocus detected 1 Severe warning sign with PPLPHARMA. Try a 7-Day Free Trial to check it out.
Volume:
3.52M
Market Cap ₹:
198.06B
Market Cap $:
2.38B
1,355.46
Avg Vol (2M):
6.55M
Enterprise Value ₹:
238.73B
Enterprise Value $:
2.87B
PB Ratio:
2.46
Alerts Website Sources Stock PDF
Dataset
Financial Download P Manual of Stocksâ„¢

Business Description

Piramal Pharma Ltd

ISIN : INE0DK501011
https://www.piramal.com
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070
Compare
Compare
BOM:533573BOM:524816BOM:543064BOM:506820BOM:540596BOM:500126BOM:540222BOM:532482BOM:524742BOM:543322ZTSXTER:MRKTSE:4502LSE:HLNNSE:SUNPHARMATSE:4523TSE:4507SZSE:000538XSWX:SDZHKSE:03692
Traded in other countries / regions
PPLPHARMA.India
IPO Date
2022-10-19
Description
Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Financial Strength

5/10
Name Current Vs Industry Vs History
Cash-To-Debt 0.14
Equity-to-Asset 0.52
Debt-to-Equity 0.6
Debt-to-EBITDA 3.44
Interest Coverage 1.02
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.33
Distress
Grey
Safe
Beneish M-Score -2.5
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 38.5
3-Year EBITDA Growth Rate 28
3-Year EPS without NRI Growth Rate -54.4
3-Year Book Growth Rate 21.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 55.98
9-Day RSI 54.35
14-Day RSI 55.39
6-1 Month Momentum % 16.6
12-1 Month Momentum % 76.46

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.25
Quick Ratio 0.75
Cash Ratio 0.15
Days Inventory 243.73
Days Sales Outstanding 84.53
Days Payable 172.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.7
Shareholder Yield % 3.62

Profitability Rank

3/10
Name Current Vs Industry Vs History
Gross Margin % 63.85
Operating Margin % 5.58
Net Margin % 0.22
FCF Margin % 3.58
ROE % 0.24
ROA % 0.12
ROIC % 0.35
ROC (Joel Greenblatt) % 8.91
ROCE % 5.74
Years of Profitability over Past 10-Year 3

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio 1355.46
PE Ratio without NRI 344.4
PS Ratio 2.28
PB Ratio 2.46
Price-to-Tangible-Book 5.45
Price-to-Free-Cash-Flow 64.29
Price-to-Operating-Cash-Flow 18.72
EV-to-EBIT 38.03
EV-to-EBITDA 17.45
EV-to-Revenue 2.93
EV-to-FCF 80.35
Price-to-Graham-Number 9.2
Earnings Yield (Greenblatt) % 2.63
FCF Yield % 1.49
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Piramal Pharma Ltd Executives

Details

GF Value

NSE:PPLPHARMA

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₹) 81,711.6
EPS (TTM) (₹) 0.109
Beta 0
Volatility % 29.96
14-Day RSI 55.39
14-Day ATR (₹) 5.295242
20-Day SMA (₹) 149.4075
12-1 Month Momentum % 76.46
52-Week Range (₹) 78.80846 - 166.7
Shares Outstanding (Mil) 1,318.02

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Piramal Pharma Ltd Filings

Filing Date Document Date Form
No Filing Data

Piramal Pharma Ltd Stock Events

Financials Calendars
Event Date Price(₹)
No Event Data

Piramal Pharma Ltd Frequently Asked Questions

What is Piramal Pharma Ltd(NSE:PPLPHARMA)'s stock price today?
The current price of NSE:PPLPHARMA is ₹150.00. The 52 week high of NSE:PPLPHARMA is ₹166.70 and 52 week low is ₹78.81.
When is next earnings date of Piramal Pharma Ltd(NSE:PPLPHARMA)?
The next earnings date of Piramal Pharma Ltd(NSE:PPLPHARMA) is .
Does Piramal Pharma Ltd(NSE:PPLPHARMA) pay dividends? If so, how much?
Piramal Pharma Ltd(NSE:PPLPHARMA) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.